Patients with SSc were linked to an increased risk for hematological malignancies, specifically B-cell malignancies.
Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ...
Jazz Pharmaceuticals plc today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026.Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided ...
The central role of Epstein-Barr virus in causing multiple sclerosis is examined to understand how it triggers the disease and presents new opportunities for treatment “Evidence is mounting that you ...
Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback